The Differential Gene Expression Pattern of Mycobacterium tuberculosis in Response to Capreomycin and PA-824 versus First-Line TB Drugs Reveals Stress- and PE/PPE-Related Drug Targets
- PMID: 20016672
- PMCID: PMC2775200
- DOI: 10.1155/2009/879621
The Differential Gene Expression Pattern of Mycobacterium tuberculosis in Response to Capreomycin and PA-824 versus First-Line TB Drugs Reveals Stress- and PE/PPE-Related Drug Targets
Abstract
Tuberculosis is a leading infectious disease causing millions of deaths each year. How to eradicate mycobacterial persistence has become a central research focus for developing next-generation TB drugs. Yet, the knowledge in this area is fundamentally limited and only a few drugs, notably capreomycin and PA-824, have been shown to be active against non-replicating persistent TB bacilli. In this study, we performed a new bioinformatics analysis on microarray-based gene expression data obtained from the public domain to explore genes that were differentially induced by drugs between the group of capreomycin and PA-824 and the group of mainly the first-line TB drugs. Our study has identified 42 genes specifically induced by capreomycin and PA-824. Many of these genes are related to stress responses. In terms of the distribution of identified genes in a specific category relative to the whole genome, only the categories of PE/PPE and conserved hypotheticals have statistical significance. Six among the 42 genes identified in this study are on the list of the top 100 persistence targets selected by the TB Structural Genomics Consortium. Further biological elucidation of their roles in mycobacterial persistence is warranted.
Figures
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915. Curr Pharm Des. 2014. PMID: 24245755
-
[Frontier of mycobacterium research--host vs. mycobacterium].Kekkaku. 2005 Sep;80(9):613-29. Kekkaku. 2005. PMID: 16245793 Japanese.
-
The interaction topology of Mycobacterium tuberculosis genes response to capreomycin and novel clues for more drug targets.J Cell Biochem. 2011 Oct;112(10):2716-20. doi: 10.1002/jcb.23232. J Cell Biochem. 2011. PMID: 21678479 Review.
-
Genome-wide exploration of the drug action of capreomycin on Mycobacterium tuberculosis using Affymetrix oligonucleotide GeneChips.J Infect. 2007 Mar;54(3):277-84. doi: 10.1016/j.jinf.2006.05.012. Epub 2006 Jul 5. J Infect. 2007. PMID: 16822547
Cited by
-
Pangenome and genomic signatures linked to the dominance of the lineage-4 of Mycobacterium tuberculosis isolated from extrapulmonary tuberculosis patients in western Ethiopia.PLoS One. 2024 Jul 25;19(7):e0304060. doi: 10.1371/journal.pone.0304060. eCollection 2024. PLoS One. 2024. PMID: 39052555 Free PMC article.
-
Genome-Wide Transcriptional Responses of Mycobacterium to Antibiotics.Front Microbiol. 2019 Feb 20;10:249. doi: 10.3389/fmicb.2019.00249. eCollection 2019. Front Microbiol. 2019. PMID: 30842759 Free PMC article. Review.
-
A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance.BMC Genomics. 2017 Oct 11;18(1):769. doi: 10.1186/s12864-017-4146-z. BMC Genomics. 2017. PMID: 29020922 Free PMC article.
-
Pretomanid for tuberculosis treatment: an update for clinical purposes.Curr Res Pharmacol Drug Discov. 2022;3:100128. doi: 10.1016/j.crphar.2022.100128. Epub 2022 Sep 9. Curr Res Pharmacol Drug Discov. 2022. PMID: 36105740 Free PMC article. Review.
-
Proteome Profiling of Mycobacterium tuberculosis Cells Exposed to Nitrosative Stress.ACS Omega. 2022 Jan 14;7(4):3470-3482. doi: 10.1021/acsomega.1c05923. eCollection 2022 Feb 1. ACS Omega. 2022. PMID: 35128256 Free PMC article.
References
-
- Zhang Y, Amzel LM. Tuberculosis drug targets. Current Drug Targets. 2002;3(2):131–154. - PubMed
-
- Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis. 2004;84(1-2):29–44. - PubMed
-
- Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis . Annual Review of Microbiology. 2001;55:139–163. - PubMed
-
- Blumberg HM, Leonard MK, Jr., Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. Journal of the American Medical Association. 2005;293(22):2776–2784. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources